Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | VDAC2 | P45880 | 1/20 | 0.63 |
| ▸ | SLC7A11 | Q9UPY5 | 1/20 | 0.63 |
| ▸ | HIF1A | Q16665 | 10/20 | 0.59 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.49 |
| ▸ | TSHR | P16473 | 2/20 | 0.49 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.49 |
| ▸ | LMNA | P02545 | 1/20 | 0.49 |
| ▸ | PKM | P14618 | 1/20 | 0.49 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.49 |
| ▸ | HTR7 | P34969 | 3/20 | 0.45 |
| ▸ | NPC1 | O15118 | 1/20 | 0.43 |
| ▸ | RAB9A | P51151 | 1/20 | 0.43 |
| ▸ | HSP90AA1 | P07900 | 1/20 | 0.42 |
| ▸ | HSP90AB1 | P08238 | 1/20 | 0.42 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL13633697 | 0.90 | VDAC2 (0.68) | VDAC2SLC7A11HIF1ASMN1; SMN2TSHR | |
| SCHEMBL13633700 | 0.90 | VDAC2 (0.68) | VDAC2SLC7A11HIF1ASMN1; SMN2TSHR | |
| SCHEMBL13633623 | 0.89 | VDAC2 (0.59) | VDAC2SLC7A11HIF1ASMN1; SMN2TSHR | |
| SCHEMBL13633662 | 0.89 | VDAC2 (0.79) | VDAC2SLC7A11HIF1ASMN1; SMN2TSHR | |
| SCHEMBL13633727 | 0.89 | VDAC2 (0.67) | VDAC2SLC7A11HIF1ASMN1; SMN2TSHR | |
| SCHEMBL13751484 | 0.89 | VDAC2 (0.67) | VDAC2SLC7A11HIF1ASMN1; SMN2TSHR | |
| SCHEMBL27256134 | 0.89 | VDAC2 (0.65) | VDAC2SLC7A11HIF1ASMN1; SMN2TSHR | |
| SCHEMBL13633615 | 0.88 | VDAC2 (0.63) | VDAC2SLC7A11HIF1ASMN1; SMN2TSHR | |
| SCHEMBL13633621 | 0.88 | VDAC2 (0.63) | VDAC2SLC7A11HIF1ASMN1; SMN2TSHR | |
| SCHEMBL27256133 | 0.88 | VDAC2 (0.70) | VDAC2SLC7A11HIF1ASMN1; SMN2TSHR |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20240207270-A1 | COMPOUNDS AND COMPOSITIONS FOR MODULATING LIPID METABOLISM | WAVEBREAK INC (US) | 2024-06-27 | — | — | US | disclosed |
| US-8518959-B2 | Quinoxaline derivatives as antitumor agents | PROLEXYS PHARMACEUTICALS, INC. (US) | 2013-08-27 | — | — | US | disclosed |
| US-7615554-B2 | Erastin and erastin binding proteins, and uses thereof | PROLEXYS PHARMACEUTICALS, INC. (US) | 2009-11-10 | — | — | US | disclosed |
| US-20090214465-A1 | Quinoxaline Derivatives as Antitumor Agents | PROLEXYS PHARMACEUTICALS, INC. (US) | 2009-08-27 | — | — | US | disclosed |
| US-20070161644-A1 | Erastin analogs and uses thereof | STOCKWELL BRENT R | 2007-07-12 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070161644-A1 | Erastin analogs and uses thereof | ERAP2, ERAP1, ERAL1 | VDAC2 3980/4885SLC7A11 1250/4885HIF1A 928/4885 |
| US-20240207270-A1 | COMPOUNDS AND COMPOSITIONS FOR MODULATING LIPID METABOLISM | CPT2, PC, SREBF2 | VDAC2 553/4885SLC7A11 906/4885HIF1A 726/4885 |
| US-20090214465-A1 | Quinoxaline Derivatives as Antitumor Agents | VDAC3, VDAC2, VDAC1 | VDAC2 2/4885SLC7A11 565/4885HIF1A 2396/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.